Top Markets
#1 Verus Coin Verus Coin +45.28%
#2 Status Status +19.17%
#3 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.58%
#4 GoPlus Security GoPlus Security +16.92%
#5 Wrapped NXM Wrapped NXM +15.51%
#6 Ontology Gas Ontology Gas +11.14%
#7 DMT-NAT DMT-NAT +9.14%
#8 BankrCoin BankrCoin +8.23%
#9 Pons Pons +7.43%
#10 Nesa Nesa +7.39%
Coin of the day
Verus Coin Verus Coin
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Renalytix Plc Renalytix Plc

Renalytix Plc

RNLX
Classifica tra le azioni #33998
Renalytix Plc, established in New York in 2018 and known as Renalytix AI plc... Renalytix Plc, established in New York in 2018 and known as Renalytix AI plc until its name change in June 2021, focuses on creating artificial intelligence-driven in vitro diagnostic tools for kidney ailments. Its primary product, KidneyIntelX, is an advanced diagnostic system that utilizes an AI-powered algorithm. This algorithm integrates multiple data sources, including scientifically validated blood markers, genetic predispositions, and individual patient information from electronic health records, to produce a distinct risk score for kidney disease. The company's technology is applied in various areas: identifying and predicting the course of kidney disease, informing clinical treatment, selecting patients for pharmaceutical trials, and discovering new therapeutic targets. Renalytix has formed several strategic collaborations, such as licensing agreements with Mount Sinai Health System for AI-assisted kidney disease diagnosis, with Joslin Diabetes Center, Inc. for developing biomarker-based kidney disease prediction products, and with Kantaro Biosciences LLC for laboratory tests to detect SARS-CoV-2 antibodies. Furthermore, it has partnered with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to introduce an innovative clinical care model aimed at improving kidney health outcomes and preventing disease advancement and failure in vulnerable populations.
Prezzo delle azioni
$0.1502
Ultima sincronizzazione: 2024-11-04
Capitalizzazione di mercato
$6.43M
Variazione (1 giorno)
-5.45%
Variazione (1 anno)
0.00%
Paese
US
Scambia Renalytix Plc (RNLX)

Categoria

Healthcare
Margine operativo per Renalytix Plc (RNLX)
Margine operativo al August 2026 TTM: -1,293.49%
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Renalytix Plc, il margine operativo attuale (TTM) è -1,293.49%. Alla fine del 2023, il margine operativo era -1,244.64%.
Storico del margine operativo per Renalytix Plc da 2018 a 2026
Margine operativo alla fine di ogni anno
Anno Margine Operativo Cambia
2026 (TTM) -1,293.49% 0.00%
2024 -1,293.49% 3.92%
2023 -1,244.64% -35.57%
2022 -1,931.72% -11.68%
2021 -2,187.19% 0.00%
2020 0.00% 0.00%
2019 0.00% 0.00%
2018 0.00% 0.00%
Margine operativo per aziende simili o concorrenti
Azienda Margine Operativo Differenza del margine operativo Il paese
GE HealthCare Technologies Inc. GE HealthCare Technologies Inc.
GE HealthCare Technologies Inc.
GEHC.US
12.70% -100.01%
US
Pro Medicus Limited Pro Medicus Limited
Pro Medicus Limited
PME.AX
74.17% -100.06%
AU
BrightSpring Health Services, Inc. Common Stock BrightSpring Health Services, Inc. Common Stock
BrightSpring Health Services, Inc. Common Stock
BTSG.US
3.33% -100.00%
US
Tempus AI, Inc. Tempus AI, Inc.
Tempus AI, Inc.
TEM.US
-19.76% -99.98%
US
Signify Health, Inc. Signify Health, Inc.
Signify Health, Inc.
SGFY.US
0.00% -
US
Cos'è l'Margine operativo di un'azienda?
L'Margine operativo è un indicatore chiave per valutare la redditività di un'azienda. Margini operativi più elevati sono generalmente preferibili poiché indicano che l'azienda riesce a vendere i propri prodotti o servizi a un prezzo significativamente superiore rispetto ai costi di produzione. Si calcola dividendo gli utili per i ricavi.